Inhibrx to webcast interim Phase 2 results of INBRX-106 combo therapy for head and neck cancer on May 11

Inhibrx Biosciences will host a live webcast on May 11, 2026, to present interim Phase 2 results from its HexAgon study. The study evaluates the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, combined with pembrolizumab versus pembrolizumab alone in first-line treatment of PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. This data is important as it may demonstrate improved treatment options for this cancer type. The webcast will be accessible online and the presentation will be available for 60 days afterward.